Literature DB >> 24958749

Gene therapy for the treatment of catecholaminergic polymorphic ventricular tachycardia.

Roger J Hajjar1, Alexander R Lyon2.   

Abstract

Entities:  

Keywords:  Editorials; calsequestrin; genetic therapy; polymorphic catecholaminergic ventricular tachycardia; ryanodine receptor release channel; sarcoplasmic reticulum

Mesh：

Substances：

Year:  2014        PMID： 24958749      PMCID： PMC5902314          DOI： 10.1161/CIRCULATIONAHA.114.010586

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  15 in total

1.  Regulatory evaluation of Glybera in Europe - two committees, one mission.

Authors:  Daniela Melchiorri; Luca Pani; Paolo Gasparini; Giulio Cossu; Janis Ancans; John Joseph Borg; Catherine Drai; Piotr Fiedor; Egbert Flory; Ian Hudson; Hubert G Leufkens; Jan Müller-Berghaus; Gopalan Narayanan; Brigitte Neugebauer; Juris Pokrotnieks; Jean-Louis Robert; Tomas Salmonson; Christian K Schneider
Journal:  Nat Rev Drug Discov       Date:  2013-08-19       Impact factor: 84.694

Review 2.  Calcium overload, spontaneous calcium release, and ventricular arrhythmias.

Authors:  Karin R Sipido
Journal:  Heart Rhythm       Date:  2006-02-28       Impact factor: 6.343

3.  Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.

Authors:  Ferran Roses-Noguer; Julian W E Jarman; Jonathan R Clague; Jan Till
Journal:  Heart Rhythm       Date:  2013-10-11       Impact factor: 6.343

4.  Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia.

Authors:  Vivek Iyer; Roger J Hajjar; Antonis A Armoundas
Journal:  Circ Res       Date:  2007-01-18       Impact factor: 17.367

5.  Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue.

Authors:  Sven T Pleger; Patrick Most; Matthieu Boucher; Stephen Soltys; J Kurt Chuprun; Wiebke Pleger; Erhe Gao; Abhijit Dasgupta; Giuseppe Rengo; Andrew Remppis; Hugo A Katus; Andrea D Eckhart; Joseph E Rabinowitz; Walter J Koch
Journal:  Circulation       Date:  2007-04-30       Impact factor: 29.690

6.  Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.

Authors:  Krisztina Zsebo; Alex Yaroshinsky; Jeffrey J Rudy; Kim Wagner; Barry Greenberg; Mariell Jessup; Roger J Hajjar
Journal:  Circ Res       Date:  2013-09-24       Impact factor: 17.367

7.  Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.

Authors:  Hiroshi Watanabe; Nagesh Chopra; Derek Laver; Hyun Seok Hwang; Sean S Davies; Daniel E Roach; Henry J Duff; Dan M Roden; Arthur A M Wilde; Björn C Knollmann
Journal:  Nat Med       Date:  2009-03-29       Impact factor: 53.440

8.  Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Marina Raffaele di Barletta; Serge Viatchenko-Karpinski; Alessandra Nori; Mirella Memmi; Dmitry Terentyev; Federica Turcato; Giorgia Valle; Nicoletta Rizzi; Carlo Napolitano; Sandor Gyorke; Pompeo Volpe; Silvia G Priori
Journal:  Circulation       Date:  2006-08-14       Impact factor: 29.690

9.  Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

10.  Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.

Authors:  Markus B Sikkel; Thomas P Collins; Christina Rowlands; Mit Shah; Peter O'Gara; Alan J Williams; Sian E Harding; Alexander R Lyon; Kenneth T MacLeod
Journal:  Cardiovasc Res       Date:  2013-01-19       Impact factor: 10.787
View more
  2 in total

1.  Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype.

Authors:  Daniel J Flores; ThuyVy Duong; Luke O Brandenberger; Apratim Mitra; Aditya Shirali; John C Johnson; Danielle Springer; Audrey Noguchi; Zu-Xi Yu; Steven N Ebert; Andreas Ludwig; Bjorn C Knollmann; Mark D Levin; Karl Pfeifer
Journal:  Hum Mol Genet       Date:  2018-05-01       Impact factor: 6.150

Review 2.  Catecholaminergic polymorphic ventricular tachycardia: An exciting new era.

Authors:  Shashank P Behere; Steven N Weindling
Journal:  Ann Pediatr Cardiol       Date:  2016 May-Aug
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.